The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 6, 2013, Pages 691-697

  Vogt, Anja ^a   Parhofer, Klaus G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

ApoB synthesis inhibitor; Familial hypercholesterolemia; LDL apheresis; LDL cholesterol; Mipomersen

Indexed keywords

EZETIMIBE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; PLACEBO;

ADULT; ANTISENSE THERAPY; APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FLU LIKE SYNDROME; GERMANY; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS B; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; GERMANY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; OLIGONUCLEOTIDES;

EID: 84875166750     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.779253     Document Type: Article

References (25)

1. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(1):3-46
2. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011;5(3 Suppl):1-8
3. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004;173(1):55-68
4. Nishimura S, Sekiguchi M, Kano T, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999;144(2):409-17
5. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis 2010;209(1):189-94
6. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975;1(7918):1208-11
7. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J (Clin Res Ed) 1985;291(6510):1671-3
8. Lane DM, McConathy WJ, Laughlin LO, et al. Selective removal of plasma low density lipoprotein with the HELP system: Biweekly versus weekly therapy. Atherosclerosis 1995;114(2):203-11
9. Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: The Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002;40(2):220-7
10. Bundesausschuss G. Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertragsarztlichen Versorgung. Bundesanzeiger 2010;109:2561
11. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010;31(23):2844-53
12. Bundesministerium fur Gesundheit. Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses uber eine Anderung der Richtlinie Methoden vertragsarztlicher Versorgung: Apherese bei isolierter Lp(a)-Erhohung. 2008
13. Wierzbicki AS, Hardman T, Viljoen A. New lipid-lowering drugs: An update. Int J Clin Pract 2012;66(3):270-80
14. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9719):998-1006
15. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105(10):1413-19
16. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010;51(5):1057-62
17. Parhofer KG. Mipomersen: Evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 2012;7:29-38
18. Bell DA, Hooper AJ, Burnett Jr. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 2011;20(2):265-72
19. Stein EA, Dufour R, Gagne C, et al. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on therapy in heterozygous familial hypercholesterolemia patients with coronary artery disease. Eur Heart J 2012;31(Suppl 1):abstract
20. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: Results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126(19):2283-92
21. Parhofer KG, Barrett PH, Demant T, et al. Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia. J Lipid Res 1996;37(11):2383-93
22. Parhofer KG, Barrett PH, Demant T. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B. J Lipid Res 2000;41(10):1596-603
23. Parhofer KG. Lipoprotein(a): Medical treatment options for an elusive molecule. Curr Pharm Des 2011;17(9):871-6
24. Visser ME, Kastelein JJ, Stroes ES. Apolipoprotein B synthesis inhibition: Results from clinical trials. Curr Opin Lipidol 2010;21(4):319-23
25. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008;198(2):247-55